Answers are grounded in this paper and cite their sources.
To compare the effectiveness and safety of pessary versus surgery in symptomatic pelvic organ prolapse. This PRISMA 2020-compliant meta-analysis (PROSPERO: CRD420251109479) searched PubMed, Embase, Web of Science, and Cochrane Library (inception: June 2025) for randomized controlled trials (RCTs) and cohort studies comparing pessary versus surgery in symptomatic POP patients. The primary outcomes included Patient Global Impression of Improvement (PGI-I) and Severity (PGI-S), pelvic floor distress inventory (PFDI-20), and related subscales (CRADI-8, UDI-6, POPDI-6). The secondary outcomes included pelvic floor impact (PFIQ-7), sexual function (PISQ-IR), and complications (e.g., urinary tract infection). Risk of bias was assessed using Cochrane tools (RCTs) and Newcastle–Ottawa Scale (cohorts). Data were pooled using random-effects models (RevMan 5.4.1), reporting standardized mean differences (SMD) or risk ratios (RR) with 95% confidence intervals (CI). Seven studies ( n = 1261 patients) were included. Surgery showed significantly greater improvement than pessary in: PGI-I (RR: 0.93; 95% CI 0.87–0.99; P = 0.03), PGI-S (RR: 0.79; 95% CI 0.66–0.96; P = 0.02), PFDI-20 (SMD: 0.23; 95% CI 0.10–0.37; P = 0.0005), CRADI-8 (SMD: 0.27; 95% CI 0.11–0.42; P = 0.001), and UDI-6 (SMD: 0.23; 95% CI 0.07–0.39; P = 0.005). However, the significance of some of the results depends on the specific study, suggesting that the conclusions should be interpreted with caution. No significant differences were found in PFIQ-7, PISQ-IR sexually active, POPDI-6, or urinary tract infection. Sensitivity analyses indicated the PGI-I and PFDI-20 superiority of surgery depended on specific studies. No publication bias was detected (Egger’s test P > 0.05). Surgical intervention demonstrates superior improvement in patient-reported symptom severity (PGI-S), global improvement (PGI-I), and specific pelvic floor distress (PFDI-20, CRADI-8, UDI-6) compared to pessary for symptomatic POP. However, both treatments showed comparable effects on quality-of-life impact (PFIQ-7), sexual function (PISQ-IR), and specific complications. Treatment choice should be individualized, considering patient factors and preferences.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: